Loading provider…
Loading provider…
Hematology & Oncology Physician in Leawood, KS
NPI: 1750355871Primary Practice Location
MENORAH MEDICAL CENTER
5721 W 119th St, Overland Park, KS
Primary Employer
Midwest Oncology Associates LLC
HCAHealthcare.com
HQ Phone
Get MD Joseph's Phone NumberMobile
Get MD Joseph's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIL State Medical License
KS State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 319 | 502 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 309 | 712 |
| 3 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 108 | 347 |
| 4 | 99223Initial hospital inpatient care, typically 70 minutes per day | 101 | 119 |
| 5 | 99203New patient outpatient visit, total time 30-44 minutes | 60 | 60 |
Authors: John Hainsworth, David Waterhouse, Howard Burris, Tarek Mekhail, Robert Whorf, Michael Mccleod, Ray Page, Dianna Shipley, David Spigel
Journal: Oncologist
Publication Date: 2019-08-16
Authors: Tracey Weisberg, Thomas Frazier, Wendy Bravo, Kevin Fox, Christine Teal, Devchand Paul, Christine Laronga, Michael Broder, Anita Mcswain
Journal: Pharmaceuticals (Basel)
Publication Date: 2015-03-17
Lead Sponsor: GlaxoSmithKline
Collaborators: iTeos Belgium SA
Intervention / Treatment: DRUG: Docetaxel, DRUG: Ipilimumab, DRUG: Dostarlimab, DRUG: GSK6097608, DRUG: Feladilimab, DRUG: GSK4428859A
Lead Sponsor: EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Intervention / Treatment: DRUG: Pembrolizumab, DRUG: M7824
Lead Sponsor: G1 Therapeutics, Inc.
Intervention / Treatment: DRUG: Placebo, DRUG: Trilaciclib